Browse editorial coverage, explainers, and reviews related to TB-500.
3 articles
TB-500's timing depends on one crucial distinction: the marketed fragment differs from the full thymosin beta-4 in human trials. Here's what the research shows—and why that separation changes everything for your protocol.
FDA has set a July 23, 2026 compounding committee review for BPC-157, TB-500, and KPV, giving these recovery peptides a concrete U.S. regulatory date. It is not approval, but it is a real access milestone.
TB-500 keeps showing up in recovery searches because it still sits near a real practical question: what does access look like now, and how do you judge sourcing without losing sight of the compound’s experimental status?